EUVIMEDEUVIMED entdecken
Crossref

Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines

Jung Gi Kim, Junchao Xu iD, Dongjae Lee, Jeongah Song, Seongjun Lee, Min Hwa Hong, Jingcheng Zhu, Audrey Zhu, Korey Patwari, Eun-Hyeon Shim, Jeong Eun Shin iD, Ok Hyun Park und 12 weitere

ACS Nano · 03.03.2026 · 20 (8) · 7022-7045

DOI: 10.1021/acsnano.5c19036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 15.02.2026. Verfasst von Jung Gi Kim und 23 weiteren Autor:innen. Beteiligte Einrichtung: Nucleic Acid Therapeutics Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang 28116, Republic of Korea. Hauptthemen laut MEDLINE: Lipids, Nanoparticles, RNA, Messenger, COVID-19 Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 99 Literaturangaben. Gefördert von: Korea Research Institute of Bioscience and Biotechnology, National Research Council of Science and Technology, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) vaccines in lipid nanoparticles (LNPs) are effective, yet immunity can wane, and reactogenicity increases with dose. We integrate ionizable lipid design, LNP formulation, and untranslated region (UTR) tuning to improve potency at low doses. From a 96-member biodegradable ionizable lipid library, stereodefined H9T6 emerged as the lead ionizable lipid. Design of experiments (DoE) identified an H9T6:DOPG:cholesterol:PEG composition (40:16:43.5:0.5 mol %) that achieved more than 3.5-fold higher dendritic-cell transfection than SM-102, increased endosomal escape, and localized expression predominantly to the injection site. For UTRs, mechanism-linked pooled screens of synthetic, barcoded randomized libraries ranked more than 630,000 3′ UTR variants by half-life in primary human nasal epithelial cells and more than 68,000 5′ UTR sequences by ribosome loading via polysome profiling, followed by predefined sequence filters consistent with efficient scanning and start codon recognition. The resulting 5B-8 scaffold outperformed benchmark UTRs from authorized mRNA vaccines in peak and cumulative antigen expression in vitro and in vivo . Encapsulation of 5B-8 mRNA in H9T6 LNPs enhanced lymph node delivery, and add-back plus receptor-blocking assays support an albumin-mediated transport mechanism. In mice, the formulation elicited strong T helper 1 (Th1)-biased humoral and cellular responses at low-microgram doses. Antibody magnitude depended primarily on UTR architecture, whereas T-cell responses reflected contributions from both the lipid and the UTR. Repeat-dose studies in rats up to 100 μg showed only transient, reversible findings without additional safety signals. These results outline a general framework for low-dose, lymph node-targeted mRNA vaccines that couples rational lipid design with mechanism-informed UTR selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipidsNanoparticlesRNA, MessengerCOVID-19 VaccinesVaccinesAnimalsHumansMicemRNA VaccinesFemaleNanovaccinesLiposomes

Stichwörter der Autor:innen

SARS-CoV-2 mRNA vaccinealbumin-mediated transportendosomal escapeionizable lipidslipid nanoparticles (LNPs)lymph node targetinguntranslated regions (UTRs)

Substanzen

LipidsRNA, MessengerLipid NanoparticlesmRNA VaccinesNanovaccinesCOVID-19 VaccinesVaccinesLiposomes

Autor:innen und Institutionen

  • Nucleic Acid Therapeutics Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang 28116, Republic of Korea.
  • mRNA Research, R&D, GC biopharma, 93, Ihyun-ro, 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924, Republic of Korea.
  • Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
  • Center for Large Animals Convergence Research, Korea Institute of Toxicology (KIT), Jeongeup 56212, Republic of Korea.
  • College of Pharmacy, Chungbuk National University College of Pharmacy, Chungbuk National University, Cheongju-si, Chungcheongbuk-do 28160, Republic of Korea.
  • Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.

ORCID-Profile: Junchao Xu, Jeong Eun Shin, Eun-Jeong Won, Jae-Hyuk Jang, Michael J Mitchell, Hyunjoo Cha-Molstad

Förderung

  • Korea Research Institute of Bioscience and Biotechnology
  • National Research Council of Science and Technology
  • National Research Foundation of Korea
  • Korea Institute of Toxicology

Zitieren

APA

Kim, J. G., Xu, J., Lee, D., Song, J., Lee, S., Hong, M. H., Zhu, J., Zhu, A., Patwari, K., Shim, E. H., Shin, J. E., Park, O. H., Rho, J., Ko, K. C., Lee, E. G., Kang, O. Y., Won, E. J., Kim, B. H., Jang, J. P., …, & Cha-Molstad, H. (2026). Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines. ACS Nano, 20(8), 7022-7045. https://doi.org/10.1021/acsnano.5c19036

Vancouver

Kim JG, Xu J, Lee D, Song J, Lee S, Hong MH, et al. Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines. ACS Nano. 2026;20(8):7022-7045. doi:10.1021/acsnano.5c19036

BibTeX
@article{Kim2026,
  author = {Kim, Jung Gi and Xu, Junchao and Lee, Dongjae and Song, Jeongah and Lee, Seongjun and Hong, Min Hwa and Zhu, Jingcheng and Zhu, Audrey and Patwari, Korey and Shim, Eun-Hyeon and Shin, Jeong Eun and Park, Ok Hyun and Rho, Jinhyung and Ko, Kyong-Cheol and Lee, Eun Gyo and Kang, On-Yu and Won, Eun-Jeong and Kim, Bo Hyeon and Jang, Jun-Pil and Jang, Jae-Hyuk and Kim, Doo-Jin and Hwang, Jeong Ho and Mitchell, Michael J and Cha-Molstad, Hyunjoo},
  title = {Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines},
  journal = {ACS Nano},
  year = {2026},
  volume = {20},
  number = {8},
  pages = {7022--7045},
  doi = {10.1021/acsnano.5c19036}
}
Kostenlos starten →